Relmada Therapeutics, Inc. risk factors: 2026 10-K against 2025
RLMD · CIK 0001553643 · SIC 2834, chemicals and allied products
Read from Form 10-K filed 2026-03-19, accession 0001213900-26-031862, against Form 10-K filed 2025-03-27, accession 0001013762-25-003426.[1] [2]
Names no risk family that the prior filing did not. Everything below was already there last year.
Tariff risk, this 10-K against the last
| Family | Status |
|---|---|
| Tariff exposure | carried over |
This company's paragraphs, both years, are in the $149 dataset
The evidence behind each status
Each status rests on paragraphs quoted from the two filings above, with their Item 1A paragraph numbers, checked against the filing text and read by two independent models. Those paragraphs are part of the dataset. The filings themselves are free on EDGAR [1] [2].
Peers in the same SIC group
- 4D Molecular Therapeutics, Inc.
- Aardvark Therapeutics, Inc.
- Abbott Laboratories
- AbCellera Biologics Inc.
- Abpro Holdings, Inc.
- Abvc Biopharma, Inc.
- Acadia Pharmaceuticals Inc
- Acrivon Therapeutics, Inc.
- Actinium Pharmaceuticals, Inc.
- Acurx Pharmaceuticals, Inc.
- Adial Pharmaceuticals, Inc.
- Adicet Bio, Inc.
Every named filer in Chemicals and allied products
Check it yourself
The filings are free. This company's 10-K filings on EDGAR are the record; the labels above are machine-generated and wrong some of the time.
References
Filings cited on this page, in the order they are first cited.
- Relmada Therapeutics, Inc.. 10-K filed 2026-03-19. Accession 0001213900-26-031862. https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm Filing index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/
- Relmada Therapeutics, Inc.. 10-K filed 2025-03-27. Accession 0001013762-25-003426. https://www.sec.gov/Archives/edgar/data/1553643/000101376225003426/ea0229064-10k_relmada.htm Filing index: https://www.sec.gov/Archives/edgar/data/1553643/000101376225003426/